Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action

Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Kitsada Wudhikarn, Beatriz Wills, Alexander M. LesokhinAbstractThe recent development of monoclonal antibodies (mAbs) has revolutionized the treatment armamentarium for multiple myeloma. The success of daratumumab and elotuzumab in relapsed/refractory patients, has generated tremendous enthusiasm for mAbs in this disease. Combination treatment with other anti-MM treatment modalities and clinical evaluation in newly diagnosed patients are expected to fundamentally change the natural history of the disease. Advances in biopharmaceutical engineering together with a robust interest in novel mAb-derivatives, including antibody drug conjugates and poly-specific antibodies are the next rapidly approaching treatment frontier in multiple myeloma. In this review, we comprehensively outline the currently available evidence and the future landscape of mAbs and mAb-derivative therapies in multiple myeloma.

Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research